Cargando…

Plasma biomarker analysis of ovarian cancer patients undergoing immunotherapy with therapeutic cancer vaccine DPX-Survivac

Detalles Bibliográficos
Autores principales:	Karkada, Mohan, Pinto, Devanand, Teh, Eve, Chisholm, Kenneth, Quinton, Tara, Berinstein, Neil, Mansour, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645511/ http://dx.doi.org/10.1186/2051-1426-3-S2-P95

Ejemplares similares

Immunological and polyfunctional T cell profiling following therapy with DPX-Survivac as a predictive tool of vaccine efficacy
por: Karkada, Mohan, et al.
Publicado: (2013)

Therapeutic vaccines and cancer: focus on DPX-0907
por: Karkada, Mohan, et al.
Publicado: (2014)

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients
por: Berinstein, Neil L, et al.
Publicado: (2015)

Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration
por: Karkada, Mohan, et al.
Publicado: (2013)

Multi-modal treatment with peptide vaccine, metronomic cyclophosphamide and anti-PD1 monoclonal antibody provides effective control of tumors in multiple models
por: Weir, Genevieve, et al.
Publicado: (2014)

CX, DPX and PRIDE: WWW servers for the analysis and comparison of protein 3D structures
por: Vlahoviček, Kristian, et al.
Publicado: (2005)

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients
por: Berinstein, Neil L, et al.
Publicado: (2012)

Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial
por: Dorigo, Oliver, et al.
Publicado: (2023)

Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response
por: Weir, Genevieve M, et al.
Publicado: (2014)

Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy
por: Tremblay, Marie-Laurence, et al.
Publicado: (2020)

Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide
por: Weir, Genevieve M., et al.
Publicado: (2016)

Cross-calibration of pencil-beam (DPX-NT) and fan-beam (QDR-4500C) dual-energy X-ray absorptiometry for sarcopenia
por: Ito, Kenyu, et al.
Publicado: (2015)

Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillusanthracis spore inhalation challenge
por: Weir, Genevieve M., et al.
Publicado: (2019)

IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers
por: Wolf, Gregory T, et al.
Publicado: (2018)

Immunotherapies in ovarian cancer
por: García-Martínez, Elena, et al.
Publicado: (2020)

Immunotherapy in Ovarian Cancer
por: Siminiak, Natalia, et al.
Publicado: (2022)

A targeted isotope dilution mass spectrometry assay for osteopontin quantification in plasma of metastatic breast cancer patients
por: Leslie, Andrew, et al.
Publicado: (2023)

Adoptive immunotherapy against ovarian cancer
por: Mittica, Gloria, et al.
Publicado: (2016)

Application Of Adoptive Immunotherapy In Ovarian Cancer
por: Yang, Siyu, et al.
Publicado: (2019)

Immunotherapy Advances for Epithelial Ovarian Cancer
por: Hartnett, Erin G., et al.
Publicado: (2020)

Ovarian Cancer Immunotherapy and Personalized Medicine
por: Morand, Susan, et al.
Publicado: (2021)

Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen
por: Berinstein, Neil L., et al.
Publicado: (2018)

Ovarian cancer immunotherapy: opportunities, progresses and challenges
por: Liu, Bei, et al.
Publicado: (2010)

Dendritic cell-based immunotherapy in ovarian cancer
por: Coosemans, An, et al.
Publicado: (2013)

Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
por: De Felice, Francesca, et al.
Publicado: (2015)

Immune checkpoints, their control by immunotherapy and ovarian cancer
por: Bose, Chinmoy K.
Publicado: (2017)

Ovarian Cancer Immunotherapy: Turning up the Heat
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
por: Yang, Chang, et al.
Publicado: (2020)

Carving a niche for immunotherapy in ovarian cancer
por: Gupta, Nitasha, et al.
Publicado: (2021)

Current and future immunotherapy approaches in ovarian cancer
por: Demircan, Nazım Can, et al.
Publicado: (2020)

Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients
por: Drucker, Arik, et al.
Publicado: (2020)

Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine
por: Wu, Di, et al.
Publicado: (2015)

Introducing the society for immunotherapy of cancer’s new journal: journal for immunoTherapy of cancer
por: Romero, Pedro J, et al.
Publicado: (2013)

Data showing the compositional complexity of the mitochondrial proteome of a unicellular eukaryote (Acanthamoeba castellanii, supergroup Amoebozoa)
por: Gawryluk, Ryan M.R., et al.
Publicado: (2014)

Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies
por: Muccioli, Maria, et al.
Publicado: (2014)

Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
por: McCloskey, Curtis W., et al.
Publicado: (2018)

Are ovarian cancer stem cells the target for innovative immunotherapy?
por: Wang, Liang, et al.
Publicado: (2018)

Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?
por: García-Martínez, Elena, et al.
Publicado: (2020)

Exosomes: A potential tool for immunotherapy of ovarian cancer
por: Gong, Xiangjin, et al.
Publicado: (2023)

Peptide Based Vaccine Approaches for Cancer—A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen
por: Naylor, Paul H., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pa5crouj620vt07kenossdoo1o